Inhibitory effect of corcin on aggregation of 1N/4R human tau protein in vitro

Document Type: Original Article

Authors

1 Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran

2 Department of Clinical Biochemistry, Tarbiat Modares University, Tehran, Iran

Abstract

Objective(s):Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. One of the hallmarks of AD is an abnormal accumulation of fibril forms of tau protein which is known as a microtubule associated protein. In this regard, inhibition of tau aggregation has been documented to be a potent therapeutic approach in AD and tauopathies. Unfortunately, the available synthetic drugs have modest beneficial efficacy with several side effects. Therefore, pipeline drugs from natural sources with anti-aggregation properties can be useful in the prevention and treatment of AD. Among medicinal plants, saffron (Crocus sativus, L.), as a traditional herbal medicine has different pharmacological properties and can be used as treatment for several nervous system impairment including depression and dementia. Crocin as a major constituent of saffron is the glycosylated form of crocetin.
Materials and Methods:  In this study, we investigated the inhibitory effect of crocin on aggregation of recombinant human tau protein 1N/4R isoform using biochemical methods and cell culture.
Results:  Results revealed that tau protein under the fibrillation condition and in the presence of crocin had enough stability with low tendency for aggregation. Crocin inhibited tau aggregation with IC50 of 100 µg/ml.  Furthermore, transmission electron microscopy images confirmed that crocin could suppress the formation of tau protein filaments.
Conclusion: Inhibitory effect of crocin could be related to its interference with nucleation phase that led to increases in monomer species of tau protein. Based on our results, crocin is recommended as a proper candidate to be used in AD treatment.

Keywords


1. Abbott A. Dementia: a problem for our age. Nature 2011; 475:S2-S4.

2. Minati L, Edginton T, Bruzzone MG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am J Alzheimers Dis Other Demen 2009; 24:95-121.

3. Reitz C, Mayeux R. Alzheimer disease: epidemio-logy, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 2014; 88:640-651.

4. De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 2012; 65:329-352.

5. Nygaard HB. Current and emerging therapies for Alzheimer's disease. Clin Ther 2013; 35:1480-1489.

6. Brunden KR, Ballatore C, Crowe A, Smith AB 3rd, Lee VM, Trojanowski JQ.Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 2010; 223:304-310.

7. Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert Opin Ther Targets 2014; 18:307-318.

8. Bulic B, Pickhardt M, Mandelkow EM, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010; 59:276-289.

9. Bulic B, Pickhardt M, Mandelkow E. Progress and developments in tau aggregation inhibitors for Alzheimer disease. J Med Chem 2013; 56:4135-4155.

10. Chiu CT, Chuang DM. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 2010; 128:281-304.

11. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 2007; 358:1-6.

12. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 2007; 28:251-260.

13. Paranjape SR, Chiang YM, Sanchez JF, Entwistle R, Wang CC, Oakley BR, Gamblin TC. Inhibition of Tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde. Planta Med 2014; 80:77-85.

14. Schafer KN, Cisek K, Huseby CJ, Chang E, Kuret J. Structural determinants of Tau aggregation inhibitor potency. J Biol Chem 2013; 288:32599-32611.

15. Monroy A, Lithgow GJ, Alavez S. Curcumin and neurodegenerative diseases. Biofactors 2013; 39:122-132.

16. Hamaguchi T, Ono K, Yamada M. REVIEW: Curcumin and Alzheimer's disease. CNS Neurosci Ther 2010; 16:285-297.

17. Cornejo A, Jiménez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer's disease. J Alzheimers Dis 2011; 27:143-153.

18. Peterson DW, George RC, Scaramozzino F, LaPointe NE, Anderson RA, Graves DJ, et al. Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease in vitro. J Alzheimers Dis 2009; 17:585-597.

19. Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB 3rd, Lee VM. Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau. J Neurochem 2009; 110:1339-1351.

20. Monti MC, Margarucci L, Riccio R, Casapullo A. Modulation of tau protein fibrillization by oleocanthal. J Nat Prod 2012; 75:1584-1588.

21. Daccache A, Lion C, Sibille N, Gerard M, Slomianny C, Lippens G, et al. Oleuropein and derivatives from olives as Tau aggregation inhibitors. Neurochem Int 2011; 58:700-707.

22. Bathaie SZ, Mousavi SZ. New applications and mechanisms of action of saffron and its important ingredients. Crit Rev Food Sci Nutr 2010; 50:761-786.

23. Hosseinzadeh H, Nassiri-Asl M. Avicenna's (Ibn Sina) the Canon of Medicine and saffron (Crocus sativus): a review. Phytother Res 2013; 27:475-483.

24. Hosseinzadeh H. Saffron: a herbal medicine of third millennium. Jundishapur J Nat Pharm Prod 2014; 9:1-2.

25. Abdullaev FI, Espinosa-Aguirre JJ. Biomedical properties of saffron and its potential use in cancer therapy and chemoprevention trials. Cancer Detect Prev 2004; 28:426-432.

26. Gohari AR, Saeidnia S, Mahmoodabadi MK. An overview on saffron, phytochemicals, and medicinal properties. Pharmacogn Rev 2013; 7:61-66.

27. Mehri S, Abnous K, Mousavi SH, Shariaty VM, Hosseinzadeh H. Neuroprotective effect of crocin on acrylamide-induced cytotoxicity in PC12 cells. Cell Mol Neurobiol 2012; 32:227-235.

28. Tamaddonfard E, Farshid AA, Asri-Rezaee S, Javadi S, Khosravi V, Rahman B, et al. Crocin improved learning and memory impairments in streptozotocin-induced diabetic rats. Iran J Basic Med Sci 2013; 16:91-100.

29. Alavizadeh SH, Hosseinzadeh H. Bioactivity assessment and toxicity of crocin: a comprehensive review. Food Chem Toxicol 2014; 64:65-80.

30. Ghahghaei A, Bathaie SZ, Kheirkhah H, Bahraminejad E. The protective effect of crocin on the amyloid fibril formation of Aβ42 peptide in vitro. Cell Mol Biol Lett 2013; 18:328-339.

31. Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis P, Margarity M,et al.  Inhibitory activity on amyloid-beta aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 2006; 54:8762-8768.

32. Uversky VN. Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res 2008; 5:260-287.

33. Bolhasani A, Bathaie S, Yavari I, Moosavi-Movahedi A, Ghaffari M. Separation and purification of some components of Iranian saffron. Asian J Chem 2005; 17:725-729.

34. Khalili MA, Riazi G, Ahmadian S, Khodarahmi R, Khodadadi S, Afrasiabi A, et al.  The role of anionic peptide fragments in 1N4R human tau protein aggregation. Protein Pept Lett 2014; 21:511-516.

35. Riazi G, Kaghazian H, RezaLornejad M, Mokhtari F, Farhadinejad S, Shahriari L, et al.  Dissimilar response of 2D and 3D astrocyte cell cultures to protective effect of recombinant human erythropoietin against amyloid-β 25-35 toxicity. Int J Pharm Sci Rev Res 2014; 24:219-226.

36. Agis-Torres A, Sölhuber M, Fernandez M, Sanchez-Montero JM. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for alzheimer's disease. Curr Neuropharmacol 2014; 12:2-36.

37. Bolognesi ML, Simoni E, Rosini M, Minarini A, Tumiatti V, Melchiorre C. Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. Curr Top Med Chem 2011; 11:2797-2806.

38. Chen X, Decker M. Multi-target compounds acting in the central nervous system designed from natural products. Curr Med Chem 2013; 20:1673-1685.

39. Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 2011; 28:439-468.

40. Calcul L, Zhang B, Jinwal UK, Dickey CA, Baker BJ. Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med Chem 2012; 4:1751-1761.

41. Howes MJ, Houghton PJ. Ethnobotanical treatment strategies against Alzheimer's disease. Curr Alzheimer Res 2012; 9:67-85.

42. Assimopoulou AN, Sinakos Z, Papageorgiou VP. Radical scavenging activity of Crocus sativus L. extract and its bioactive constituents. Phytother Res 2005; 19:997-1000.

43. Nam KN, Park YM, Jung HJ, Lee JY, Min BD, Park SU, et al.  Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 2010; 648:110-116.

44. Geromichalos GD, Lamari FN, Papandreou MA, Trafalis DT, Margarity M, Papageorgiou A, et al. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. J Agric Food Chem 2012; 60:6131-6138.

45. Meraz-Ríos MA, Lira-De León KI, Campos-Peña V, De Anda-Hernández MA, Mena-López R. Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 2010; 112:1353-1367.

46. Dolai S, Shi W, Corbo C, Sun C, Averick S, Obeysekera D, et al. Clicked" sugar-curcumin conjugate: modulator of amyloid-β and tau peptide aggregation at ultralow concentrations. ACS Chem Neurosci 2011; 2:694-699.

47. Mousavi SH, Tayarani NZ, Parsaee H. Protective effect of saffron extract and crocin on reactive oxygen species-mediated high glucose-induced  toxicity in PC12 cells. Cell Mol Neurobiol 2010; 30:185-191.

48. Ochiai T, Shimeno H, Mishima K, Iwasaki K, Fujiwara M, Tanaka H, et al. Protective effects of carotenoids from saffron on neuronal injury in vitro and in vivo. Biochim Biophys Acta 2007; 1770:578-584.

49. Mohamadpour AH, Ayati Z, Parizadeh MR, Rajbai O, Hosseinzadeh H. Safety evaluation of crocin (a constituent of saffron) tablets in healthy volunteers. Iran J Basic Med Sci 2013; 16:39-46.

50. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al.           A 22-week, multicenter, randomized,double-blind controlled trial of Crocus sativus in the treatment  of mild-to-moderate Alzheimer's disease. Psycho-pharmacology (Berl) 2010; 207:637-643.